T1	Participants 116 179	patients with previously untreated metastatic colorectal cancer
T2	Participants 483 550	previously untreated metastatic colorectal carcinoma (CRC) patients
T3	Participants 654 891	Between May 1996 and July 1997, 380 patients were randomized to receive either UFT (300 mg/m(2)/d) and LV (90 mg/d), administered for 28 days every 35 days, or 5-FU (425 mg/m(2)/d) and LV (20 mg/m(2)/d), given IV for 5 days every 35 days
T4	Participants 1995 2009	metastatic CRC
